ENGNW (STOCKS)
enGene Therapeutics Inc. Warrants
—
Change: —
Prev close: —
Company Information
- Exchange
- XNAS
- Sector
- —
- Industry
- —
- CEO
- —
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 57
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $5.28M |
| Operating Expenses | $127.74M |
| Research and Development | $96.76M |
| Other Operating Expenses | $30.98M |
| Operating Income/Loss | -$127.74M |
| Income/Loss From Continuing Operations After Tax | -$122.44M |
| Income/Loss From Continuing Operations Before Tax | -$122.46M |
| Income Tax Expense/Benefit | -$18.00K |
| Net Income/Loss | -$122.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$122.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$122.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.25 |
| Diluted Earnings Per Share | $2.25 |
| Basic Average Shares | 169,468,169 |
| Diluted Average Shares | 169,468,169 |
| Common Stock Dividends | $0.00 |
| Assets | $337.11M |
| Current Assets | $289.22M |
| Noncurrent Assets | $47.90M |
| Fixed Assets | $2.44M |
| Other Non-current Assets | $45.46M |
| Liabilities | $55.57M |
| Current Liabilities | $24.61M |
| Accounts Payable | $2.44M |
| Wages | $5.90M |
| Other Current Liabilities | $16.27M |
| Noncurrent Liabilities | $30.96M |
| Equity | $281.55M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $281.55M |
| Liabilities And Equity | $337.11M |
| Net Cash Flow From Operating Activities | -$102.45M |
| Net Cash Flow From Operating Activities, Continuing | -$102.45M |
| Net Cash Flow From Investing Activities | -$66.47M |
| Net Cash Flow From Investing Activities, Continuing | -$66.47M |
| Net Cash Flow From Financing Activities | $143.18M |
| Net Cash Flow From Financing Activities, Continuing | $143.18M |
| Exchange Gains/Losses | $1.00K |
| Net Cash Flow | -$25.73M |
| Net Cash Flow, Continuing | -$25.73M |
| Comprehensive Income/Loss | -$122.31M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$122.01M |
| Other Comprehensive Income/Loss | -$28.86M |
| Other Comprehensive Income/Loss Attributable To Parent | $433.00K |